Humanised monoclonal antibody therapy for rheumatoid arthritis.

Monoclonal antibodies that target T cells have shown some benefit in rheumatoid arthritis although responses have not been long lasting. This is partly due to insufficient therapy consequent upon antibody immunogenicity. Use of humanised antibodies, which are expected to be less foreign to man than...

ver descrição completa

Detalhes bibliográficos
Main Authors: Isaacs, J, Watts, R, Hazleman, B, Hale, G, Keogan, M, Cobbold, S, Waldmann, H
Formato: Journal article
Idioma:English
Publicado em: 1992
_version_ 1826278619098382336
author Isaacs, J
Watts, R
Hazleman, B
Hale, G
Keogan, M
Cobbold, S
Waldmann, H
author_facet Isaacs, J
Watts, R
Hazleman, B
Hale, G
Keogan, M
Cobbold, S
Waldmann, H
author_sort Isaacs, J
collection OXFORD
description Monoclonal antibodies that target T cells have shown some benefit in rheumatoid arthritis although responses have not been long lasting. This is partly due to insufficient therapy consequent upon antibody immunogenicity. Use of humanised antibodies, which are expected to be less foreign to man than conventional rodent antibodies, might overcome this problem. We therefore assessed in a phase 1 open study the potential of a "lymphocyte depleting" regimen of the humanised monoclonal antibody CAMPATH-1H in 8 patients with refractory rheumatoid arthritis. Apart from symptoms associated with first infusions of antibody, adverse effects were negligible. Significant clinical benefit was seen in 7 patients, lasting for eight months in 1. After one course of therapy, there was no measurable antiglobulin response, although 3 out of 4 patients have become sensitised on retreatment. Humanisation reduces the immunogenicity of rodent antibodies but anti-idiotype responses may still be seen on repeated therapy, even in patients sharing immunoglobulin allotype with the humanised antibody.
first_indexed 2024-03-06T23:46:38Z
format Journal article
id oxford-uuid:7125b1e6-80fb-414b-bdae-e9ffdf095397
institution University of Oxford
language English
last_indexed 2024-03-06T23:46:38Z
publishDate 1992
record_format dspace
spelling oxford-uuid:7125b1e6-80fb-414b-bdae-e9ffdf0953972022-03-26T19:41:43ZHumanised monoclonal antibody therapy for rheumatoid arthritis.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:7125b1e6-80fb-414b-bdae-e9ffdf095397EnglishSymplectic Elements at Oxford1992Isaacs, JWatts, RHazleman, BHale, GKeogan, MCobbold, SWaldmann, HMonoclonal antibodies that target T cells have shown some benefit in rheumatoid arthritis although responses have not been long lasting. This is partly due to insufficient therapy consequent upon antibody immunogenicity. Use of humanised antibodies, which are expected to be less foreign to man than conventional rodent antibodies, might overcome this problem. We therefore assessed in a phase 1 open study the potential of a "lymphocyte depleting" regimen of the humanised monoclonal antibody CAMPATH-1H in 8 patients with refractory rheumatoid arthritis. Apart from symptoms associated with first infusions of antibody, adverse effects were negligible. Significant clinical benefit was seen in 7 patients, lasting for eight months in 1. After one course of therapy, there was no measurable antiglobulin response, although 3 out of 4 patients have become sensitised on retreatment. Humanisation reduces the immunogenicity of rodent antibodies but anti-idiotype responses may still be seen on repeated therapy, even in patients sharing immunoglobulin allotype with the humanised antibody.
spellingShingle Isaacs, J
Watts, R
Hazleman, B
Hale, G
Keogan, M
Cobbold, S
Waldmann, H
Humanised monoclonal antibody therapy for rheumatoid arthritis.
title Humanised monoclonal antibody therapy for rheumatoid arthritis.
title_full Humanised monoclonal antibody therapy for rheumatoid arthritis.
title_fullStr Humanised monoclonal antibody therapy for rheumatoid arthritis.
title_full_unstemmed Humanised monoclonal antibody therapy for rheumatoid arthritis.
title_short Humanised monoclonal antibody therapy for rheumatoid arthritis.
title_sort humanised monoclonal antibody therapy for rheumatoid arthritis
work_keys_str_mv AT isaacsj humanisedmonoclonalantibodytherapyforrheumatoidarthritis
AT wattsr humanisedmonoclonalantibodytherapyforrheumatoidarthritis
AT hazlemanb humanisedmonoclonalantibodytherapyforrheumatoidarthritis
AT haleg humanisedmonoclonalantibodytherapyforrheumatoidarthritis
AT keoganm humanisedmonoclonalantibodytherapyforrheumatoidarthritis
AT cobbolds humanisedmonoclonalantibodytherapyforrheumatoidarthritis
AT waldmannh humanisedmonoclonalantibodytherapyforrheumatoidarthritis